Summary
MOFSL maintains a bullish outlook on Sun Pharma, projecting a 16% upside due to the company's innovation pipeline and strong Q1 results. Strategic initiatives like semaglutide launches and the Organon acquisition are expected to drive significant growth, particularly in specialty and innovative medicines.